NCT00422487View on ClinicalTrials.gov

Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

September 30, 2007

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MBX-2044

MBX-2044 1.5 mg one capsule daily for 14 days

DRUG

MBX-2044

MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days

DRUG

MBX-2044

MBX-2044 15 mg one capsule daily for 14 days

DRUG

MBX-2044

MBX-2044 30 mg two 15 mg capsules daily for 14 days

DRUG

MBX-2044

MBX-2044 60 mg one capsule daily for 14 days

DRUG

MBX-2044

MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days

DRUG

Placebo for MBX-2044

Placebo Intervention

Trial Locations (1)

78229-4801

Diabetes and Glandular Disease Research Associates, San Antonio

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY